{"title":"常染色体显性多囊肾病的肾移植","authors":"Andrzej Kulesza, L. Niemczyk, M. Niemczyk","doi":"10.33590/emjnephrol/10311490","DOIUrl":null,"url":null,"abstract":"Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 1 in 1,000 people in the general population. The natural history of ADPKD includes the progression of chronic kidney disease to end-stage renal disease (ESRD) in a large proportion of patients. Renal transplantation is the treatment modality of choice in these patients. However, there are some specific issues that should be addressed in ADPKD, and the aim of the current review is to describe the issues that need to be considered in the pre and post-transplant management of ADPKD patients, excluding routine procedures.","PeriodicalId":348431,"journal":{"name":"EMJ Nephrology","volume":"217 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":"{\"title\":\"Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease\",\"authors\":\"Andrzej Kulesza, L. Niemczyk, M. Niemczyk\",\"doi\":\"10.33590/emjnephrol/10311490\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 1 in 1,000 people in the general population. The natural history of ADPKD includes the progression of chronic kidney disease to end-stage renal disease (ESRD) in a large proportion of patients. Renal transplantation is the treatment modality of choice in these patients. However, there are some specific issues that should be addressed in ADPKD, and the aim of the current review is to describe the issues that need to be considered in the pre and post-transplant management of ADPKD patients, excluding routine procedures.\",\"PeriodicalId\":348431,\"journal\":{\"name\":\"EMJ Nephrology\",\"volume\":\"217 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-07-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"EMJ Nephrology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.33590/emjnephrol/10311490\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"EMJ Nephrology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33590/emjnephrol/10311490","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Renal Transplantation in Autosomal Dominant Polycystic Kidney Disease
Autosomal dominant polycystic kidney disease (ADPKD) affects approximately 1 in 1,000 people in the general population. The natural history of ADPKD includes the progression of chronic kidney disease to end-stage renal disease (ESRD) in a large proportion of patients. Renal transplantation is the treatment modality of choice in these patients. However, there are some specific issues that should be addressed in ADPKD, and the aim of the current review is to describe the issues that need to be considered in the pre and post-transplant management of ADPKD patients, excluding routine procedures.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
